To answer your first question, very simply, yes. We should 100% be thinking about it from the very start.
Something that some other jurisdictions are doing, which we're starting to do but haven't historically done in Canada, is co-locating, for example, processing at the facilities where isotopes are being produced. Bruce Power has just installed some hot cells at their facility to start doing some of the processing, but historically a lot of the processing of isotopes has happened abroad.
As we're looking at new nuclear, if we're going to be selecting reactors that can produce isotopes, certainly, we should be thinking about that from the start and seeing how we can do things like processing locally to the reactors.
On your second question, I don't think we have enough time for me to tell you everything I'd like to see in the radioisotope strategy. The key for us is broad engagement, first of all, not just with industry—obviously, we're an industry association—but also with health care. We can produce endless volumes of isotopes, but if we don't have the medical workforce in Canada to deliver those isotopes to patients, that's a real barrier.
Not to harp on processing, but I also think an expanded focus on processing would be key in that strategy. As I say, historically, using the lutetium example at Bruce Power, a lot of that has been processed in Germany. Some of that could be brought to Canada, potentially, to shore up our domestic supply chain. That's a big one for me.
We do process. For example, cobalt-60 is processed just down the road in Kanata, Ontario, so we do have some capabilities domestically, but from the CNIC's perspective, bringing some more processing to Canada would be key as part of that strategy.
